Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Auteurs : Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart-Gebhart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Jaar : 2013
Journal : Cancer
Volume : 119(10)
Pagina's : 1908-15